Search - tctmd.com

Displaying 121 - 140 of 379

Sort: Relevancy | Date

Presentation TCT 2021

One-year Outcomes of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions

Presenter: Bruno Scheller

November 06, 2021

Presentation TCT 2021

A Randomized Trial of Sirolimus-coated Versus Paclitaxel-coated Balloons in De Novo Coronary Lesions

Presenter: Wan Azman Wan Ahmad

November 06, 2021

Presentation TCT 2021

The MAGICAL trial – Insights from the upcoming US IDE DCB study

Presenter: Martin Leon

November 05, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

Yael L. Maxwell

March 03, 2021

News Industry News

MagicTouch SCB Granted 'Breakthrough Device Designation' for the treatment of Small Coronary Artery Lesions.

December 16, 2020

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

The OPTIMIZE IDE: TrialProspective, Randomized Evaluation of Sirolimus-Eluting Coronary Stents with Fixed-Wire and Rapid-Exchange Delivery Systems and a Novel Bioresorbable Drug Carrier

Presentation TCT 2020

OPTIMIZE IDE: Trial Prospective, Randomized Evaluation of Sirolimus-Eluting Coronary Stents with Fixed-Wire and Rapid-Exchange Delivery Systems and a Novel Bioresorbable Drug Carrier

Presenter: Dean J. Kereiakes

October 17, 2020

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

Presentation TCT 2020

TCT 529: 12-y/o Female Patient Treated With a Second-Generation Tyrocore Sirolimus-Eluting Bioresorbable Scaffold in a Denovo Coronary Stenosis in the Donor Heart After Transplantation

Presenter: Matthias Lutz

October 14, 2020

Advertisement

One-year Outcomes of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions

A Randomized Trial of Sirolimus-coated Versus Paclitaxel-coated Balloons in De Novo Coronary Lesions

The MAGICAL trial – Insights from the upcoming US IDE DCB study

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case

MagicTouch SCB Granted 'Breakthrough Device Designation' for the treatment of Small Coronary Artery Lesions.

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

OPTIMIZE IDE: Trial Prospective, Randomized Evaluation of Sirolimus-Eluting Coronary Stents with Fixed-Wire and Rapid-Exchange Delivery Systems and a Novel Bioresorbable Drug Carrier

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

TCT 529: 12-y/o Female Patient Treated With a Second-Generation Tyrocore Sirolimus-Eluting Bioresorbable Scaffold in a Denovo Coronary Stenosis in the Donor Heart After Transplantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content